APA (7th ed.) Citation

Maura C. Gillis, B., Vanessa R. Weir, B., Cecilia Lezcano, M., Gopa Iyer, M., & Allison Gordon, M. Use of dupilumab to manage a grade 3 cutaneous adverse effect from enfortumab vedotin/pembrolizumab treatment in a patient with metastatic urothelial carcinoma. Elsevier.

Chicago Style (17th ed.) Citation

Maura C. Gillis, BA, BA Vanessa R. Weir, MD Cecilia Lezcano, MD Gopa Iyer, and MD Allison Gordon. Use of Dupilumab to Manage A grade 3 Cutaneous Adverse Effect from Enfortumab Vedotin/pembrolizumab Treatment in A patient with Metastatic Urothelial Carcinoma. Elsevier.

MLA (9th ed.) Citation

Maura C. Gillis, BA, et al. Use of Dupilumab to Manage A grade 3 Cutaneous Adverse Effect from Enfortumab Vedotin/pembrolizumab Treatment in A patient with Metastatic Urothelial Carcinoma. Elsevier.